Kazia Therapeutics Plans to Trade Solely on Nasdaq, Delist From ASX

By Josh Beckerman


Sydney-based Kazia Therapeutics plans to trade solely on Nasdaq and delist its securities from the Australian Securities Exchange.

According to a Friday filing with the Securities and Exchange Commission, the oncology-focused drug company requested trading halts of its American depositary shares and its ASX-listed shares pending a company announcement. It expects to make the announcement to ASX before the commencement of normal trading on Tuesday.

Before the late Thursday U.S. halt, ADSs were down 6.5% after hours to 89 cents following a 4.5% increase in the regular session.


Write to Josh Beckerman at [email protected]


Read the full article here